Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Sanofi
Thumbnail
June 22, 2022

To buy or build blockbusters?

A look at blockbuster origins shows the role of external innovation, but more of these huge franchises are in the hands of their inventors than ever before.

Thumbnail
June 14, 2022

Roche deal fails to Repare the licensing scene

Few sizeable transactions have emerged so far this year, with small licensing deals looking like the norm.

Article image
Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.

Article image
Vantage logo
June 07, 2022

Asco 2022 – looking beyond Enhertu in Her2-low cancer

Article image
Vantage logo
June 07, 2022

Lebrikizumab’s convenience edge emerges

Article image
Vantage logo
June 04, 2022

Asco 2022 – Merck’s follow-on immuno-oncology plan hits a myositis problem

ILT3 blockade shows no monotherapy activity while a combo runs into toxicity issues, but Merck presses on.

Article image
Vantage logo
June 03, 2022

Turning Point and Libtayo steal some pre-Asco thunder

On the eve of Asco two deals show that the current biotech market malaise might be focusing some chief executives’ minds.

Article image
Vantage logo
June 01, 2022

US FDA approval tracker: May

Article image
Vantage logo
May 31, 2022

Go or no go? The FDA’s Amylyx dilemma

June will see adcoms aplenty, with Bluebird, Acadia, and the Covid vaccine makers Novavax, Pfizer/Biontech and Moderna all facing FDA committees.

Article image
Vantage logo
May 31, 2022

GSK goes back to its vaccine bread and butter

But breaking Pfizer and Merck’s duopoly will not be easy.

Article image
Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

New extended consensus forecasts from Evaluate Pharma show Roche edged out of first place by Abbvie as new blood replaces Humira.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.